Details

Autor(en) / Beteiligte

• Kaplan, Muhammet Ali
• Isikdogan, Abdurrahman
• Koca, Doğan
• Kucukoner, Mehmet
• Gumusay, Ozge
• Yildiz, Ramazan
• Dayan, Adem
• Demir, Lütfiye
• Geredeli, Caglayan
• Kocer, Murat
• Arslan, Ulku Yalcintas
• İnal, Ali
• Akman, Tulay
• Coskun, Ugur
• Sener, Nur
• Inanc, Mevlude
• Elkiran, Emin Tamer
• Ozdemir, Nuriye Yildirim
• Durnalı, Ayse Gok
• Suner, Ali
• Alici, Suleyman
• Tarhan, Mustafa Oktay
• Boruban, Cem
• Oksuzoglu, Berna
• Urakci, Zuhat

Titel

Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Society of Medical Oncology

Ist Teil von

• Breast cancer (Tokyo, Japan), 2014-11, Vol.21 (6), p.677-683

Ort / Verlag

Tokyo: Springer Japan

Erscheinungsjahr

2014

Quelle

MEDLINE

Beschreibungen/Notizen

• Purpose In this study, we investigated the effect of lapatinib plus capecitabine treatment in HER2-positive breast cancer patients with brain metastasis. Methods Of 405 metastatic breast cancer patients with brain metastases at referral centers in Turkey, 46 were treated with lapatinib plus capecitabine only after the development of brain metastasis. Patients who only received trastuzumab-based therapy after the development of brain metastases were accepted as the historic control group for survival analyses ( n  = 65). Patients who received both drugs consecutively or sequentially were excluded from the analyses ( n  = 34). Results Median age among 46 patients who received lapatinib plus capecitabine therapy was 45 years (27–76), and median time for development of brain metastases was 11.9 months (0–69 months). Twenty-six out of 38 patients who received lapatinib plus capecitabine and had extracranial metastasis showed partial response or stable diseases (68.4 %). Grade 3-4 toxicity was observed in eight patients (17.3 %). Median overall survival (OS) in patients treated with lapatinib plus capecitabine was significantly increased compared to that in patients treated with trastuzumab-based therapy (19.1 vs. 12 months, respectively, p  = 0.039). The incidence of cerebral death was slightly decreased in patients who received lapatinib plus capecitabine compared to those who received trastuzumab-based therapy (32 vs. 43.4 %, p  = 0.332). In the multivariate analysis, lapatinib plus capecitabine therapy remained an independent positive predictor for survival [odds ratio (OR), 0.57; p  = 0.02]. Discussion Although this retrospective multicenter study had several limitations, the results suggest that undergoing lapatinib plus capecitabine therapy after the diagnosis of brain metastasis may further improve survival compared to undergoing only trastuzumab-based therapy.